Protara Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$64.5 | -$49.2 | -$43.6 | -$67.1 | -$47.5 |
| Net income | -$57.4 | -$44.6 | -$40.4 | -$66.0 | -$47.3 |
| Cash Flow Statement | |||||
| Free cash flow | -$56.5 | -$35.9 | -$37.6 | -$26.6 | -$35.1 |
| Share repurchases | — | — | $0.1 | $0.1 | $0.2 |
Shares outstanding 56.2M · Free float 85.6%
Annual filing data through FY ended December 31, 2025; float as of August 25, 2026.